General method for the C-labeling of 2-arylpropionic acids and their esters: Construction of a PET tracer library for a study of biological events involved in COXs expression

Chemistry - A European Journal

Volumn 16, Issue 14, 2010, Pages 4250-4258

  Takashima Hirano, Misato ^a   Shukuri, Miho ^a   Takashima, Tadayuki ^a   Goto, Miki ^a   Wada, Yasuhiro ^a   Watanabe, Yasuyoshi ^a   Onoe, Hirotaka ^a   Doi, Hisashi ^a   Suzuki, Masaaki ^a  

^a RIKEN   (Japan)

Author keywords

Anti inflammatory drugs; C c coupling; Cyclooxygenase; Inflammation; Positron emission tomography

Indexed keywords

ACIDS; ALKYLATION; BIOCHEMISTRY; DRUG PRODUCTS; ESTERIFICATION; ESTERS; HYDROLYSIS; LABELING; METHYLATION; PATHOLOGY; POSITRONS; SYNTHESIS (CHEMICAL);

ANTI-INFLAMMATORY DRUGS; ARYLPROPIONIC ACIDS; BASIC CONDITIONS; BIOLOGICAL FUNCTIONS; C-C COUPLING; CYCLOOXYGENASE; CYCLOOXYGENASES; ENOLATE INTERMEDIATES; FLURBIPROFEN; GENERAL METHOD; IN-VIVO; IN-VIVO IMAGING; KETOPROFEN; LIPOPOLYSACCHARIDES; METABOLITE ANALYSIS; METHYL ESTERS; MICROPET; NAPROXENS; NEUROINFLAMMATION; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; ONE POT; PET TRACER; RADIOLABELING; RAT BRAIN;

POSITRON EMISSION TOMOGRAPHY;

CARBON; CYCLOOXYGENASE 2 INHIBITOR; ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHARMACOLOGY; PROPIONIC ACID DERIVATIVE; PROSTAGLANDIN SYNTHASE;

ANIMAL; ARTICLE; BLOOD; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; INFLAMMATION; METABOLISM; METHODOLOGY; METHYLATION; POSITRON EMISSION TOMOGRAPHY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD; BRAIN; CARBON RADIOISOTOPES; CHEMISTRY; CYCLOOXYGENASE 2 INHIBITORS; ENZYMOLOGY; ESTERS; INFLAMMATION; METABOLISM; METHODS; METHYLATION; MOLECULAR STRUCTURE; PHARMACOLOGY; POSITRON-EMISSION TOMOGRAPHY; PROPIONIC ACIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77950846318     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.200903044     Document Type: Article

References (53)

1. J. G. Lombardino, Nonsteroidal Antiinflammatory Drugs, Wiley, New York, 1985.
2. N. V. Chandrasekharan, H. Dai, K. L. T. Roos, N. K. Evanson, J. Tomsik, T. S. Elton, D. L. Simmons, Proc. Natl. Acad. Sci. USA 2002, 99, 13926-13931.
3. a) M. E. Phelps PET: Molecular Imaging and its Biological Applications, Springer, New York, 2004;
4. b) J. S. Fowler, A. P. Wolf, Acc. Chem. Res. 1997, 30, 181-188;
5. c) S. M. Ametamey, Chem. Rev. 2008, 108, 1501-1516;
6. d) P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. 2008, 120, 9136-9172;
7. Angew. Chem. Int. Ed. 2008, 47, 8998-9033.
8. G. Lappin, R. C. Garner, Nat. Rev. Drug Discovery 2003, 2, 233-240.
9. M. Bergström, R. J. Hargreaves, H. D. Burns, M. R. Goldberg, D. Sciberras, S. A. Reins, K. J. Petty, M. Ögren, G. Antoni, B. Långström, O. Eskola, M. Scheinin, O. Solin, A. K. Majumdar, M. L. Constanzer, W. P. Battisti, T E. Bradstreet, C. Gargano, J. Hietala, Biol. Psychiatry 2004, 55, 1007-1012.
10. a) M. Suzuki, K. Sumi, H. Koyama, Siqin, T. Hosoya, M. Takashima-Hirano, H. Doi, Chem. Eur. J. 2009, 15, 12489-12495;
11. b) H. Doi, I. Ban, A. Nonomiya, K. Sumi, C. Kuang, T. Hosoya, H. Tsukada, M. Suzuki, Chem. Eur. J. 2009, 15, 4165-4171;
12. c) M. Suzuki, H. Doi, M. Björkman, Y. Andersson, B. Långström, Y. Watanabe, R. Noyori, Chem. Eur. J. 1997, 3, 2039-2042.
13. a) H. R. Herschman, J. J. Talley, R. DuBois, Mol. Imaging. Biol. 2003, 5, 286-303;
14. b) E. F. de Vries, Curr. Pharm. Des. 2006, 12, 3847-3856;
15. c) S. T. Elder, Diss. Abstr. Int. B 1991, 52, 2566.
16. E. F. de Vries, A. van Waarde, A. R. Buursma, W. Vaalburg, J. Nucl. Med. 2003, 44, 1700-1706.
17. J. Prabhakaran, V. J. Majo, N. R. Simpson, R. L. Van Heertum, J. J. Mann, J. S. D. Kumar, J. Labelled Compd. Radiopharm. 2005, 48, 887-895.
18. E. F. de Vries, J. Doorduin, R. A. Dierckx, A. van Waarde, Nucl. Med. Biol. 2008, 35, 35-42.
19. V. J. Majo, J. Prabhakaran, N. R. Simpson, R. L. Van Heertum, J. J. Mann, J. S. D. Kumar, Bioorg. Med. Chem. Lett. 2005, 15, 4268-4271.
20. M. Tanaka, Y. Fujisaki, K. Kawamura, K. Ishiwata, Qinggeletu, F. Yamamoto, T. Mukai, M. Maeda, Biol. Pharm. Bull. 2006, 29, 2087-2094.
21. a) T. J. McCarthy, A. U. Sheriff, M. J. Graneto, J. J. Talley, M. J. Welch, J. Nucl. Med. 2002, 43, 117-124;
22. b) Y. Fujisaki, K. Kawamura, W. F. Wang, K. Ishiwata, F. Yamamoto, T. Kuwano, M. Ono, M, Maeda, Ann. Nucl. Med. 2005, 19, 617-625;
23. c) F. R. Wüst, A. Hohne, P. Metz, Org. Biomol. Chem. 2005, 3, 503-507;
24. d) J. Prabhakaran, M. F. Underwood, R. V. Parsey, V. Arango, V. J. Majo, N. R. Simpson, R. Van Heertum, J. J. Mann, J. S. D. Kumar, Bioorg. Med. Chem. 2007, 15, 1802-1807;
25. e) F. Wuest, T. Kniess, R. Bergmann, J. Pietzsch, Bioorg. Med. Chem. 2008, 16, 7662-7670.
26. a) J. E. Dinchuk, B. D. Car, R. J. Focht, J. J. Johnston, B. D. Jaffee, M. B. Covington, N. R. Contel, V. M. Eng, R. J. Collins, P. M. Czerniak, S. A. Gorry, J. M. Trzaskos, Nature 1.995, 378, 406-409;
27. b) R. Langenbach, C. Loftin, C. Lee, H. Tiano, Biochem. Pharmacol. 1999, 58, 1237-1246;
28. c) R. Langenbach, S. G. Morham, H. F. Tiano, C. D. Loftin, B. I. Ghanayem, P. C. Chulada, J. F. Mahler, C. A. Lee, E. H. Goulding, K. D. Kluckman, H. S. Kim, O. Smithies, Cell 1995, 83, 483-492;
29. d) S. G. Morham, R. Langenbach, C. D. Loftin, H. F. Tiano, N. Vouloumanos, J. C. Jennette, J. F. Mahler, K. D. Kluckman, A. Ledford, C. A. Lee, O. Smithies, Cell 1995, 83, 473-482;
30. e) J. L. Wallace, A. Bak, W. McKnight, S. Asfaha, K. A. Sharkey, W. K. MacNaughton, Gastroenterology 1998, 115, 101-109.
31. M. Takashima-Hirano, Y. Cui, T. Takashima, E. Hayashinaka, Y. Wada, Y. Watanabe, H. Doi, M. Suzuki, J. Labelled Compd Radiopharm. 2009, 52, S435.
32. 11C][14]methyl-fatty acids was reported, it requires three steps including methylation, hydrolysis, and decarboxylation to give our desired compounds. See reference: K. Ogawa, M. Sasaki, T Nozaki, Appl. Radiat, Isot. 1997, 48, 623-630.
33. a) T. D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, X R. Vane, Proc. Natl. Acad. Sci. USA 1999, 96, 7563-7568;
34. b) D. Riendeau, M. Salem, A. Styhler, M. Ouellet, J. A. Mancini, C. S. Li, Bioorg. Med. Chem. Lett. 2004, 14, 1201-1203.
35. a) H. Fujisawa, T. Fujiwara, Y. Takeuchi, K. Omata, Chem. Pharm. Bull. 2005, 53, 524-528;
36. b) T. Bruzzese, M. Cambieri, R. Ferrari, Ger. Offen. DE2614306, 1976;
37. c) J. H. Fried, I. T. Harrison, S. African ZA6707597, 1968;
38. d) S. S. Adams, J. Bernard, J. S. Nichlolson, A. R. Biancafort, U.S. Patent 3755427, 1973;
39. e) Y. L. Chen, U.S. Patent 2005032859, 2005;
40. f) D. E. Bays, R. V. Foster, S.African ZA6804682, 1969;
41. g) A. Terada, E. Misaka, K. Hasegawa, Fr. Demande FR2483918, 1981.
42. a) T. Fukumura, R. Y. Nakao, M. Yamaguchi, K. Suzuki, Appl. Radiat. Isot. 2004, 61, 1279-1287;
43. b) P. J. H. Scott, B. G. Hockley, H. F. Kung, R. Machanda, W. Zhang, M. R. Kilbourn, Appl. Radiat. Isot. 2009, 67, 88-94.
44. All products were isolated as a racemic mixture. Generally, the S enantiomer of 2-arylproiponic acid is pharmacologically active in terms of the cyclooxygenase inhibition. However, the majority of 2arylpropionic acids are prepared in a racemic mixture because an isomerase enzyme (2-arylpropionyl-CoA pimerase) exists in vivo system that converts the inactive R enantiomer into the active S form, see: a) C. Reichel, R. Brugger, H. Bang, G. Geisslinger, K. Brune, Mol. Pharmacol. 1997, 51, 576-582; exceptionally, a few inhibitors, such as Flurbiprofen, undergo such a bioconversion to a very little extent in vitro or in vivo systems, see:
45. b) D. D. Leipold, D. Kantoci, E. D. Murray, D. D. Quiggle, W. J. Wechter, Chirality 2004, 16, 379-387;
46. -1; UV detection: 254 nm). If necessary, the use of an optically active PET tracer will be reported with the detailed resolution method in due course.
47. H. B. Choi, J. K. Ryu, S. U. Kim, J. G. McLarnon, J. Neurosci. 2007, 27, 4957-4968.
48. J. L. Eriksen, S. A. Sagi, T. E. Smith, S. Weggen, P. Das, D. C. McLendon, V. V. Ozols, K. W. Jessing, K. H. Zavitz, E. H. Koo, T. E. Golde, J. Clin. Invest. 2003, 112, 440-449.
49. a) O. Inoue, R. Hosoi, S. Momosaki, K. Yamamoto, M. Amitani, M. Yamaguchi, A. Gee, Nucl. Med. Biol. 2006, 33, 985-989;
50. b) S. Momosaki, R. Hosoi, T. Sanuki, K. Todoroki, M. Yamaguchi, A. Gee, O. Inoue, Nucl. Med. Biol. 2007, 34, 939-944.
51. V. W. Pike, Trends Pharmacol. Sci. 2009, 30, 431-440.
52. It should be added that this rapid methylation could also be applied to other 2-arylpropionic acid derivatives of NSAIDs, such as, Benoxaprofen, Cycloprofen, Pranoprofen, etc. to form a larger PET tracer library.
53. B. Långstrom, G. Antoni, P. Gullberg, G Halldin, P. Malmborg, K. Nagren, A. Rimland, H. Svard, J. Nucl. Med. 1987, 28, 1037-1040.